BTK and autoimmune thrombocytopenic purpura: Bruton’s tyrosine kinase (BTK) is also expressed by PLTs, and rilzabrutinib, a BTK inhibitor, which reduces macrophages-induced PLT destruction, has been investigated for the management of ITP.